SCHEMBL13664245

SCHEMBL13664245

CC(C(=O)c1nn(-c2ccc(Cl)cc2)c(N)c1C#N)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GAA P10253 2/20 0.46
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
KDM4E B2RXH2 3/20 0.41
ABCB1 P08183 2/20 0.41
CYP1A2 P05177 1/20 0.40
HIF1A Q16665 1/20 0.40
CNR1 P21554 1/20 0.40
PSD A5PKW4 1/20 0.38
CHEK1 O14757 1/20 0.37
KCNH2 Q12809 1/20 0.37
RIPK1 Q13546 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664174 0.81 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664235 0.78 MAPT (0.49) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664230 0.78 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664246 0.77 MAPT (0.48) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664217 0.77 MAPT (0.49) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664157 0.75 GAA (0.58) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664233 0.74 MAPT (0.46) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL12100341 0.74 KDM4E (0.60) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664161 0.74 MAPT (0.51) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL13664223 0.74 MAPT (0.52) MAPTMEN1KMT2ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885MEN1 3462/4885KMT2A 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.